

Arzeda expands protein design capabilities with new \$38M funding to advance commercialization efforts globally

07 November 2024 | News

Aims to meet global market demand of better tasting stevia and accelerate the commercialization



Aims to meet global market demand of better tasting stevia and accelerate the commercialization

Arzeda, the Protein Design Company, has concluded \$38M oversubscribed funding round to expand the production capacity of its ProSweet Enzymes and ProSweet RebM to meet strong market demand of better tasting stevia and accelerate the commercialization of additional breakthrough products in its pipeline. Arzeda has partnered with several global industrial leaders to bring these products to the market including Unilever, AAK, and W.L. Gore & Associates.

The new investments is in collaboration with Sofinnova Partners, Fall Line Capital, Sucden Ventures, Silver Blue, and the venture arm of W.L. Gore & Associates (makers of Gore-Tex®), which has been in a joint development agreement with Arzeda since 2022. Previous investors also participated in the round, including the venture arm of the Continental Grain Company, Bunge Ventures, and Lewis & Clark Agrifood.

“Arzeda is at a key inflection point with its products now at commercial scale,” said Michael Krel, Partner at Sofinnova Partners. “This funding will enable Arzeda to accelerate the commercialization of its industrial biotech products, including new designer proteins and enzymes that have the ability to reduce GHG emissions. Arzeda’s Intelligent Protein Design Technology is transformational to many industrial verticals and they are one of the few companies that have been able to translate this promise into commercial products that solve real-world problems and create value for the customer.”

Arzeda’s Intelligent Protein Design Technology is built on one of the largest proprietary datasets of high-quality protein designs linked to experimental results and leverages the latest advances in generative artificial intelligence (AI) to design and manufacture higher-performing proteins and enzymes tailored for large-scale production. Arzeda’s proteins and enzymes enable alternatives which outperform existing products across various industries, including food, personal and home care, agriculture, chemicals, materials, pharmaceuticals, and diagnostics, in a more sustainable manner.

The biotech industry has only scratched the surface of what can be done with designed proteins, and Arzeda is on a mission to make this future a reality. Alexandre Zanghellini, co-founder and CEO of Arzeda said “The field of protein design has experienced explosive growth in recent years but has faced challenges in translating these advances into products. Where we excel is in developing solutions that can be manufactured sustainably at scale.”